Fundamental analysis: Ambrx Biopharma Inc. (AMAM)

Awarener score: could not be estimated

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (could not be estimated), the business stability (could not be estimated) and growth (could not be estimated), and the company's inclination to return cash to the stockholders (could not be estimated).

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: a result could not be reached

Business growth could not be estimated, due to not enough input data. It's been unavailable to compare with peer companies.
Ambrx Biopharma Inc. business stability could not be estimated, due to insufficient input data. It looks we cannot compare it to rivals.

Margins score: we could not reach a conclusion

AMAM usual gross margins were not estimated, due to lack of enough history. They stand unknown against rival companies.
We would not risk estimating the normal operating margins, because of insufficient past records. It's unidentified in relation to competitors.
Normal EBITDA margins remain unknown, due to not enough track records. They remain unknown against peers.
EBIT normal margins could not be estimated, due to not sufficient input years. They're still undisclosed compared to similar companies.
Usual profit margin before income taxes is still unknown, as there is not enough history to analyze, and remain therefore an impossibility to compare with rivals.
Due to insufficient past records, we were unable to estimate normal net profit margin. Company stands unidentified in relation to comparable firms.

Growth score: could not be analyzed

Ambrx Biopharma Inc. has an unknown gross margin growth, as there is not enough data to analyze. It's been impossible to compare to competitors.
There is not sufficient data to estimate the operating income margin trend, which has been therefore unknown against comparable firms.
EBITDA growth is unknown due to insufficient inputs, which compares unknown against peer enterprises.
We were not able to provide an estimate for EBIT growth, because of lacking data. It turns to be not yet known in relation to similar stocks.
Profit before income tax growth was not estimated, on insufficient history. It was impossible to measure against rivals.
Net income growth could not be estimated, and so it is unknown against peer companies.
There was not enough input data to estimate EPS trend. It's been an impossibility to compare it with industry peers.

Miscellaneous score: remains unknown

AMAM has an unknown effective tax rate, due to insufficient data. It's been incomparable against peers.
The company does not report R&D expenses. It's meaningless to measure in relation to competitors.
We have insufficient data to estimate how effective is research and development effort. It stands unknown against rival companies.

Profitability score: could not be estimated

Ambrx Biopharma Inc. remains a mystery in terms of normal return on assets (ROA), as there are not enough past records. It proves a real challenge to compare it with peer firms.
Due to insufficient track history, we were unable to estimate typical returns on invested capital (ROIC). They remain undisclosed in relation to similar companies.
Normal return on equity (ROE) is unavailable at this time, because of not enough yearly inputs to calculate. It ranks unknown against competitors.
A normalized return on tangible assets (ROTA) is unavailable, due to insufficient data. It's unknown in relation to comparable enterprises.

Usage of Funds score: we were unable to estimate a total

AMAM remains pending of analysis regarding capital expenditures, due to data unavailable. It stands unknown in relation to rival firms.
The relationship between capital expenditures and depreciation is not known, because of not enough inputs, which is a big question mark in relation to industry peers.
There was no available information regarding dividend yield. It came unknown against competitors.
The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
Shares count analysis is unavailable, on lacking data. It remains we cannot compare it with peer enterprises.
We are not sure on the effectiveness of the company when repurchasing shares, as there were not enough numbers to crunch. It stands unidentified against rivals.
We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: a result could not be reached

Ambrx Biopharma Inc. has not disclosed intangibles assets, so we could not reach a meaningful conclusion on this metric. It happens to be a not known variable when measured with peer companies.
Current ratio remains a mystery, as there was not sufficient Balance Sheet information. It turns to be unidentifiable against similar firms.
The relation between debt and assets is unknown to us. It remains undisclosed against rival firms.
We have not enough inputs to assess how quickly assets can be turned into cash and equivalents. It looks we are not able to reach a conclusion in relation to rivals.
Quick ratio is unavailable at this moment, due to lacking data. It's a pity we cannot compare it with peer firms.
A conclusion on cash ratio could not be reached, as we lack inputs, which is unfortunate when trying to measure against similar enterprises.
Days of sales outstanding are not known, out of lack of data. It still ranks unknown against peers.
Days of inventory outstanding are not known. It comes up as a big question mark against competitors.
We could not gauge the normal operating cycle of the company. It happens to be a mystery against peers.
Unfortunately, we had not enough data to estimate the days of payables outstanding. It ranks unknown against industry peers.
Cash conversion cycle remains unknown, due to not having enough inputs. It's incomparable against similar companies.
To what extent normalized EBITDA covers interest expenses is not known. It stands impossible to compare against rival firms.
There is insufficient data to conclude on the relationship of EBITDA and debt for this company. It ranks unknown against comparable enterprises.
Fixed assets turnover remains undisclosed. It looks we cannot relate it to similar firms.
We did not reach a conclusion regarding total assets turnover, as not enough data is currently available. It's still unable to match with peer companies.

Valuation score: could not be gauged

Ambrx Biopharma Inc. has an unknown adjusted Price-to-Earnings ratio, so we cannot comment on that. It happens to be a necessary comparison against competitors.
We have not enough data to conclude on the relationship of price versus tangible book value for this company. It remains therefore unknown compared to peers.
There is insufficient information on the genuine funds generation capability showed in the past twelve months, which stands as an incognita in relation to similar companies.
Unfortunately, lack of enough yearly data impaired our ability to estimate the normal earnings power. It's still an unknown variable to measure against industry firms.
A conclusion regarding usual company rewards to stockholders was impossible to reach with data available. It came up also not enough to relate to peer ventures.
We are unsure on the relationship between net financial position and market capitalization of the stock. It looks we will not be able to reach a conclusion regarding similar enterprises.
Traditional Price-to-Earnings is unavailable. It ranks unknown against peer companies.
Price-to-Sales ratio is currently an incognita. It looks incomparable with rival firms.
We have not enough information on the relation between current stock price and accounting book value. The company remains a mystery against peer firms.
We could not gauge an alternative metric of earnings power of the past twelve months. It happens to be an interesting metric to relate to industry peers.
An alternate metric on the usual genuine-funds generation ability could not be provided. It's still unknown against peer companies.

Total score: could not be summarized

Company at a glance: Ambrx Biopharma Inc. (AMAM)

Sector, industry: Healthcare, Biotechnology

Market Cap: 0.82 billions

Revenues TTM: unavailable

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.